My Companies
Notification
Account
Log Out
Login
Biocon Biologics received Japan’s MHLW marketing approval for its pegfilgrastim biosimilar to Neulasta®. Sandoz K.K. will exclusively promote, sell and distribute the product in Japan, expanding Biocon’s biosimilar portfolio in the market.
Biocon Launches Yesafili Aflibercept Biosimilar in United States
Biocon Launches Yesafili Aflibercept Biosimilar Commercially In United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal